Literature DB >> 9461298

Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases.

M P d'Ortho1, H Will, S Atkinson, G Butler, A Messent, J Gavrilovic, B Smith, R Timpl, L Zardi, G Murphy.   

Abstract

Soluble proenzyme forms of the catalytic domains of membrane-type matrix metalloproteinases 1 and 2 (MT1-MMP and MT2-MMP) and a form of MT1-MMP containing the catalytic and hemopexin domains were expressed as soluble recombinant proteins. Purified, activated forms of the MT-MMP were shown to degrade fibronectin, tenascin, nidogen, aggrecan and perlecan. Only MT2-MMP showed activity against laminin. MT1-MMP retaining the hemopexin domain was able to specifically cleave native type-I and type-III collagens into the 3/4-1/4 fragments typical of the specific collagenases. The catalytic domain alone did not retain this activity. The MT-MMP did not degrade interleukin-1beta, but, similarly to many other MMP, could process a pro [tumor necrosis factor (TNF) alpha] fusion protein to release mature TNF. However, the latter was subsequently degraded into smaller fragments. These results demonstrate that, in addition to their ability to activate other MMP, such as progelatinase A/proMMP2 and procollagenase-3/proMMP13, MT-MMP degrade a number of extracellular matrix macromolecules. Their location at the surface of cells implies that they could play a significant role in the modulation of cell-matrix interactions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9461298     DOI: 10.1111/j.1432-1033.1997.00751.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  127 in total

1.  Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I.

Authors:  Z Zhou; S S Apte; R Soininen; R Cao; G Y Baaklini; R W Rauser; J Wang; Y Cao; K Tryggvason
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

Review 2.  MMPs and TIMPs--an historical perspective.

Authors:  J Frederick Woessner
Journal:  Mol Biotechnol       Date:  2002-09       Impact factor: 2.695

3.  Membrane-type MMPs are indispensable for placental labyrinth formation and development.

Authors:  Ludmila Szabova; Mee-Young Son; Joanne Shi; Marek Sramko; Susan S Yamada; William D Swaim; Patricia Zerfas; Stacie Kahan; Kenn Holmbeck
Journal:  Blood       Date:  2010-09-21       Impact factor: 22.113

4.  Variability in melanoma metalloproteinase expression profiling.

Authors:  Orsi Giricz; Janelle L Lauer; Gregg B Fields
Journal:  J Biomol Tech       Date:  2010-12

5.  MT1-MMP-mediated basement membrane remodeling modulates renal development.

Authors:  Karen S Riggins; Glenda Mernaugh; Yan Su; Vito Quaranta; Naohiko Koshikawa; Motoharu Seiki; Ambra Pozzi; Roy Zent
Journal:  Exp Cell Res       Date:  2010-08-19       Impact factor: 3.905

6.  BST-2 binding with cellular MT1-MMP blocks cell growth and migration via decreasing MMP2 activity.

Authors:  Gongping Gu; Dejian Zhao; Ziming Yin; Ping Liu
Journal:  J Cell Biochem       Date:  2012-03       Impact factor: 4.429

7.  MMP14 Regulates Cranial Neural Crest Epithelial-to-Mesenchymal Transition and Migration.

Authors:  Taylor Garmon; Megen Wittling; Shuyi Nie
Journal:  Dev Dyn       Date:  2018-09-09       Impact factor: 3.780

8.  Expression of MT1-MMP during deciduous tooth resorption in odontoclasts.

Authors:  Busayarat Linsuwanont-Santiwong; Yuzo Takagi; Keiichi Ohya; Hitoyata Shimokawa
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

9.  Characterization and regulation of MT1-MMP cell surface-associated activity.

Authors:  Sonia Pahwa; Manishabrata Bhowmick; Sabrina Amar; Jian Cao; Alex Y Strongin; Rafael Fridman; Stephen J Weiss; Gregg B Fields
Journal:  Chem Biol Drug Des       Date:  2018-12-19       Impact factor: 2.817

10.  Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor.

Authors:  C Fernandez-Catalan; W Bode; R Huber; D Turk; J J Calvete; A Lichte; H Tschesche; K Maskos
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.